AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

Registry ID: R3918-PNH-2050
Source registry: HEALTH_CANADA
Status: Ongoing
Study type: INTERVENTIONAL
Sponsor: REGENERON PHARMACEUTICALS INC
Start date: 2025-12-09
Last update: 2022-10-06

Conditions

PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

Related clinical trials

A SINGLE ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WITH INADEQUATE CONTROL OF INTRAVASCULAR HEMOLYSIS ON CURRENTLY AVAILABLE C5 INHIBITOR THERAPY
A PHASE 3 OPEN-LABEL STUDY OF DANICOPAN AS ADD-ON TREATMENT TO RAVULIZUMAB OR ECULIZUMAB IN PEDIATRIC PARTICIPANTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO HAVE CLINICALLY SIGNIFICANT EXTRAVASCULAR HEMOLYSIS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF ALN-CFB, AN INVESTIGATIONAL SIRNA THERAPEUTIC AGAINST COMPLEMENT FACTOR B, IN PARTICIPANTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND PERSISTENT ANEMIA ON APPROVED C5-INHIBITOR THERAPY
LONG-TERM EXTENSION (LTE) STUDY TO CHARACTERIZE THE SAFETY AND EFFICACY OF DANICOPAN AS AN ADD-ON THERAPY TO A COMPLEMENT COMPONENT 5 INHIBITOR (C5I) IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PREVIOUSLY TREATED WITH DANICOPAN IN AN ALEXION-SPONSORED CLINICAL STUDY
A RANDOMIZED, OPEN-LABEL, RAVULIZUMAB-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO ARE COMPLEMENT INHIBITOR TREATMENT-NAIVE OR HAVE NOT RECENTLY RECEIVED COMPLEMENT INHIBITOR THERAPY
AN OPEN-LABEL, NON-RANDOMIZED, MULTI-CENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF APL-2 IN THE TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

View on source registry